- Report
- August 2022
- 118 Pages
Global
From €4564EUR$4,750USD£3,924GBP
- Report
- January 2024
- 200 Pages
Japan
From €5525EUR$5,750USD£4,751GBP
- Report
- September 2022
- 159 Pages
Global
From €7206EUR$7,500USD£6,197GBP
- Report
- December 2022
- 112 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- August 2022
- 119 Pages
Global
From €4324EUR$4,500USD£3,718GBP
- Drug Pipelines
- February 2019
- 300 Pages
Global
From €21139EUR$22,000USD£18,177GBP
- Report
- May 2020
- 218 Pages
Global
From €10565EUR$10,995USD£9,084GBP
- Report
- April 2018
Global
From €961EUR$1,000USD£826GBP
- Report
- November 2023
- 111 Pages
China
From €1730EUR$1,800USD£1,487GBP
- Clinical Trials
- January 2020
- 500 Pages
Global
From €2306EUR$2,400USD£1,983GBP
- Report
- November 2023
- 105 Pages
Global
From €3500EUR$3,902USD£3,115GBP
- Report
- April 2023
- 71 Pages
Global
From €3500EUR$3,902USD£3,115GBP
- Report
- January 2021
- 141 Pages
China, Global
From €3000EUR$3,345USD£2,670GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,189GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,189GBP
- Report
- November 2023
- 239 Pages
China
From €3843EUR$4,000USD£3,305GBP
- Report
- November 2021
- 844 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Report
- November 2021
- 575 Pages
Global
From €3843EUR$4,000USD£3,305GBP
- Report
- April 2023
- 147 Pages
Global
From €5764EUR$5,999USD£4,956GBP
Rivastigmine is a drug used to treat symptoms of Alzheimer's disease and other forms of dementia. It is a cholinesterase inhibitor, meaning it works by increasing the amount of a chemical messenger in the brain that helps nerve cells communicate with each other. It is used to treat mild to moderate dementia caused by Alzheimer's disease or Parkinson's disease. It is also used to treat mild to moderate dementia caused by Lewy body dementia. Rivastigmine is available in both capsule and patch form.
Rivastigmine is part of the Central Nervous System (CNS) drugs market, which includes drugs used to treat neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. CNS drugs are used to treat a wide range of conditions, from mild to severe. The CNS drugs market is highly competitive, with many companies offering similar products.
Some companies in the Rivastigmine market include Novartis, Pfizer, Mylan, and Teva Pharmaceuticals. Show Less Read more